DIRS.INFO The most relevant business & tech news

☆ Chipmaker Analog Devices' forecasts held back by inventory corrections
▼ + stars: | 2023-11-21 | by ( ) www.reuters.com time to read: +2 min

Analog Devices' logo is pictured on a smartphone in this illustration taken, December 4, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsNov 21 (Reuters) - Chipmaker Analog Devices (ADI.O) projected first-quarter revenue and profit below market estimates on Tuesday, as it grapples with the ongoing supply glut in the semiconductor industry. Inflation-hit customers have refrained from placing new orders for chips, leading to excess supply at companies such as Analog Devices after a pandemic-driven buying spree fizzled out. First-quarter adjusted earnings are expected to be $1.70 per share, plus or minus 10 cents, below analysts' average estimates of $1.90. Cautious spending by automakers fearing a slowdown in their electric-vehicle businesses has also weighed on orders at Analog Devices.

Persons: Dado Ruvic, Vincent Roche, Arsheeya, Tasim Zahid Organizations: REUTERS, Texas, Analog Devices, Thomson Locations: Bengaluru

☆ Stocks may crash 30%, a recession looks imminent, and commercial real estate is a bubble about to burst, market prophet says. Here are Gary Shilling's 8 best quotes from a new interview.
▼ + stars: | 2023-11-19 | by ( Theron Mohamed | ) www.businessinsider.com time to read: +4 min

Market prophet Gary Shilling issued a raft of dire warnings to investors in an interview this week. Stocks may crash 30%, a recession is imminent, and commercial real estate is a bubble about to burst, he said. AdvertisementStocks could crater by 30%, the US economy is careening toward recession, and commercial real estate is a bubble about to burst, a legendary market prophet warned this week. "I think the biggest bubble right now is commercial real estate. This isn't of the magnitude of the subprime-mortgage bonanza, but I think it is a bubble which is beginning to crack."

Persons: Gary Shilling, Shilling, —, Julia La Roche, I've, they've, we're, John Paulson Organizations: Service, Federal Reserve

☆ Prepare for stocks to plummet 30% and a recession to strike any day now, legendary market prophet says
▼ + stars: | 2023-11-17 | by ( Theron Mohamed | ) www.businessinsider.com time to read: +3 min

Stocks could plummet by as much as 30%, a legendary Wall Street forecaster has said. He said he was betting on Treasury bonds and the US dollar and against stocks and commodities. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementPrepare for stocks to plunge by a third and a recession to strike imminently, a legendary market forecaster has said. "You'd have a further decline of about 30% from here to get that 40% overall decline, peak to trough," he said.

Persons: Gary Shilling, —, I've, Julia La Roche, we're, Shilling, Merrill Lynch's, he's Organizations: Wall, Service, Co, Reserve

☆ Stocks making the biggest moves premarket: Tyson Foods, Boeing, Monday.com and more
▼ + stars: | 2023-11-13 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines before the bell: Monday.com — Shares of the project management company jumped 10% after Monday.com reported a strong quarter and issued a rosy forecast. Monday.com reported third-quarter earnings and revenue of 64 cents per share on revenue of $189.2 million. Tyson Foods — The food products company fell 3.3% in premarket trading after Tyson's fiscal fourth-quarter revenue came in weaker than expected. Boeing — Shares rose 3.25% after Emirates Airlines announced the purchase of 95 Boeing aircraft for a total of $52 billion. TripAdvisor — Shares of the online booking company added 2.3% after Bernstein upgraded TripAdvisor to outperform from market perform.

Persons: Monday.com, FactSet, Matt Gline, Roche, Bernstein, GitLab, Henry Schein, — CNBC's Michelle Fox, Alex Harring, Jesse Pound, Pia Singh Organizations: Tyson, Boeing, Emirates Airlines, Sciences, Roivant Sciences, Revenue, HP Inc, Citi

☆ Google might have to delay its plan to kill tracking cookies until 2025, ad industry experts believe
▼ + stars: | 2023-11-09 | by ( Lara O'Reilly | ) www.businessinsider.com time to read: +6 min

There are growing rumblings within the ad industry that Google won't be able to get rid of third-party tracking cookies until 2025 at the earliest. It has since delayed that plan twice to give the ad industry more time to prepare, but has repeatedly said it's on track for a fourth-quarter, 2024 cookie expiry date. "It's a mess," said one ad industry executive speaking on condition of anonymity in order to talk freely about the process. The CMA's latest Privacy Sandbox update listed various concerns from various constituents about the proposals. Despite some skepticism that Google can hit its 2024 deadline, many in the ad industry just want to move past third-party cookies after almost four years in limbo.

Persons: James Rosewell, Rosewell, Achim Schlosser, there's, —, Paul Bannister, Bannister, Mathieu Roche Organizations: Google, UK's, Markets Authority, CMA, Movement, European netID Foundation, Publishers, Yahoo

☆ Bayer examines break-up options and prepares to cut management jobs
▼ + stars: | 2023-11-08 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Bayer will remove multiple layers of management and coordination for a "significant reduction" in the workforce, it said. "We are redesigning Bayer to focus only on what’s essential for our mission – and getting rid of everything else," said Anderson. Analysts have said Bayer shares are trading at a massive discount to rivals in agriculture, pharmaceuticals and consumer health activities, partly weighed down by a preference among many financial investors for pure-play companies. Bayer reported third-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) and adjusted for one-off effects fell 31% to 1.685 billion euros, hit by lower earnings at its Crop Science division. Bayer added that it expects a "soft growth outlook and continued challenges" to profitability next year.

Persons: Wolfgang Rattay, Bill Anderson, Anderson, Bayer, Werner Baumann, Ludwig Burger, Miranda Murray, David Goodman Organizations: Bayer AG, REUTERS, Rights, Bayer, Consumer, Roche, Science, Thomson Locations: Leverkusen, Germany

☆ The U.S. can avoid a recession, David Roche says
▼ + stars: | 2023-11-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe U.S. can avoid a recession, David Roche saysDavid Roche, president and global strategist at Independent Strategy, says "American households have done nothing but get richer."

Persons: David Roche Organizations: Independent

☆ How Whitney Wolfe Herd's fateful deal with a Russian mogul deprived early Bumble employees of a stock windfall when she became a billionaire
▼ + stars: | 2023-11-06 | by ( Ben Bergman | ) www.businessinsider.com time to read: +23 min

I'm fucking done," she told a reporter at Time, who described Wolfe Herd as "blinking back tears" during the interview. "My hands are tied," Wolfe Herd told the audience, according to several people who were in the room. Wolfe Herd once called him her biggest mentor, saying, "He's become my family and one of my best friends." Some early employees said they only found out about the shadow-equity program, and who received it, years later. Based on the current share price, Wolfe Herd is no longer a billionaire, though her fortune still sits at an estimated $627 million.

Persons: Whitney Wolfe Herd, Andrey Andreev, Wolfe Herd, Bumble, Whitney Wolfe, Wolfe, Bumble wasn't, Charley Gallay, I've, Robbie McKay, McKay, Jerod Harris, Sarah Mick, Bumble's, That's, Mick, Justin Mateen, Tinder, Antoine Antoniol, Andreev, What's, He's, —, Jody Thelander, Alexandra Williamson, Samantha Fulgham, Chelsea Maclin, Caroline Ellis Roche, Michael Herd, they'd, Taylor, they're, Vivien Killilea, didn't, Charles Elson, Elson, Blackstone, Forbes, Ben Bergman Organizations: Worldwide Vision, Nasdaq, Carlton, Getty, Fortune, Andreev's, TechCrunch, Southwest, telltale, Founders, Chelsea, Austin, Ritz, Mailchimp, Intuit, University of Delaware, Twitter Locations: Russian, Austin, Los Angeles , California, Bumble, Northern California, Deer Valley , Utah, Punta Mita , Mexico, Tinder, London, Bermuda, WVL, San Francisco, Texas, Positano, Italy, Bay, Atlanta, MagicLab, Badoo, bbergman@insider.com

☆ Siemens Healthineers reviews options for diagnostics unit -source
▼ + stars: | 2023-11-03 | by ( ) www.reuters.com time to read: +1 min

A staffer works on a magnetic resonance imaging machine at a production line of Siemens Healthineers in Shenzhen, China May 25, 2018. REUTERS/Bobby Yip/File Photo Acquire Licensing RightsMUNICH/FRANKFURT, Nov 3 (Reuters) - German medical equipment maker Siemens Healthineers (SHLG.DE) is in the early stages of weighing options for its diagnostics business, which has little overlap with other units, a person familiar with the situation told Reuters. The review could lead to a sale of the unit but all options remain open, the source said. The diagnostics business is also in the middle of restructuring. The listed Siemens subsidiary ranks number two worldwide behind Swiss Roche (ROG.S) in the business of laboratory lines for blood tests.

Persons: Bobby Yip, Alexander Huebner, Victoria Farr, Utkarsh, Bill Berkrot, Jason Neely Organizations: Siemens, REUTERS, Reuters, Bloomberg, Swiss Roche, Thomson Locations: Shenzhen, China, FRANKFURT, Swiss, Munich, Emma, Frankfurt, Bengaluru

☆ David Beckham: Filmmaker Fisher Stevens explains how ‘Succession’ and Leonardo DiCaprio helped land him Netflix documentary series
▼ + stars: | 2023-10-29 | by ( Don Riddell | Glen Levy | ) edition.cnn.com time to read: +7 min

CNN —At first glance, the American actor and filmmaker Fisher Stevens wasn’t the obvious choice to helm the four-part Netflix documentary series about English soccer great David Beckham. “When they first called me, my response was …’why me for David Beckham?’” the 59-year-old said to CNN Sport’s Don Riddell. “I said, ‘Hey, I have a call with David Beckham, but I’m not sure,’” Fisher fondly recalled. I say what’s really strong, their relationship is really strong and if you can work with your wife and it works, God bless, man,” he said. But that’s why he’s also such a good guy, because he’s worried about you too.”A second series?

Persons: Fisher Stevens, David Beckham, Stevens, ’, CNN Sport’s Don Riddell, “, ”, Beckham, Alex Ferguson, Ballon d’Or, Lionel Messi, ” Adams, Taylor Swift, Travis Kelce, Becks ’, Jesse Armstrong, HBO’s, Tony Roche, Hugo, Oscar, Leonardo DiCaprio, DiCaprio, ‘, I’m, ’ ” Fisher, Logan Roy, ” Brand Beckham, David, he’s, “ Beckham, Ted, Ferguson, Scot, Megan Briggs, Victoria, ‘ David we’ll, ‘ David, that’s, Joseph West, ” Stevens Organizations: CNN, Netflix, Manchester United, Major League Soccer, Inter Miami, Argentina, Spice, HBO, Warner Bros, United, Real Madrid, Variety, Qatar, Jewish Locations: American, England, Spain, America, Italy, France, United States, “, Victoria

☆ Investors reject Sanofi's cure to sickly valuation
▼ + stars: | 2023-10-27 | by ( ) www.reuters.com time to read: +3 min

LONDON, Oct 27 (Reuters Breakingviews) - Sanofi (SASY.PA) investors dislike CEO Paul Hudson’s prescription to reinvigorate the pharmaceutical group’s weak valuation. Analysts polled by LSEG expect the division to hit an EBIT of 1.6 billion euros this year. On listed rival Haleon’s 15.6 times multiple, that business could be worth 25 billion euros. The rest of the Sanofi business may generate EBIT of 11.4 billion euros. The problem is that investors don’t appear to want to take the harsh medicine that leads to a cure.

Persons: Paul Hudson’s, Ernst & Young, Sanofi, EBIT, Roche, Karen Kwok, Francesco Guerrera, Streisand Neto Organizations: Reuters, Sanofi, Ernst, LSEG, Novartis, Novo Nordisk, GSK, AstraZeneca, X, Unilever, Thomson

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

☆ US growth boom tees up year-end bust
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

The latest report on the country's growth is worth celebrating, but not for too long. Household incomes after inflation and taxes fell by $71 billion in the third quarter, according to Pantheon Macroeconomics. That shrank in the third quarter, with managers flagging peak interest rates as a larger concern, leaving less in the pipeline. Yet stores spent $81 billion in excess inventory last quarter and are likely to wait to restock shelves. Last quarter’s boom should give way to a bust.

Persons: Lee Jae, LSEG, Ben Winck, Lauren Silva Laughlin, Sharon Lam Organizations: Rights, Reuters, Macroeconomics, Savings, Companies, X, Unilever, Thomson Locations: U.S

☆ New-look Unilever retains its old-style opacity
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

Unilever logo is displayed on Dove soap boxes in this illustration taken on January 17, 2022. Back in 2017 Unilever fought off a Kraft Heinz (KHC.O) takeover approach by pledging a 20% operating margin; now there just isn’t a target. But it leaves a question mark over Unilever’s long-term direction. And it might leave long-term critics like fund manager Terry Smith still griping about opacity. In January Smith complained that Unilever had revealed the price tag on only three of 27 acquisitions in its Beauty and Wellbeing division over eight years.

Persons: Dado Ruvic, Hein Schumacher’s, Kraft Heinz, Alan Jope, Terry Smith, Smith, Schumacher, George Hay, Peter Thal Larsen, Oliver Taslic Organizations: Unilever, REUTERS, Reuters, Kraft, X, Thomson

☆ Ford’s electric drive is going the wrong way
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Rebecca Cook Acquire Licensing RightsNEW YORK, Oct 26 (Reuters Breakingviews) - Ford Motor (F.N) may have dealt with its labor problem. While the ebb and flow of fossil-fueled fortunes is nothing new, Ford’s electric-car pivot is printing more red ink than ever. But Ford is trying to scale to profitable sales and right now, things are going the wrong way. The company’s electric division recorded a nearly $37,000 operating loss per battery-powered ride sold this quarter, 51% worse than last year. With once sky-high electric prices now free-falling, Ford faces the brass-tacks problem of simply grinding down costs.

Persons: Jim Farley, Rebecca Cook, can’t, nix, Ford, Jonathan Guilford, Lauren Silva Laughlin, Aditya Sriwatsav Organizations: Ford Motor, North American, REUTERS, Reuters, Ford, General Motors, Cox, X, Unilever, Thomson Locations: Detroit , Michigan, U.S, Detroit

☆ Amazon's grey cloud is the new blue sky
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Mike Blake Acquire Licensing RightsNEW YORK, Oct 26 (Reuters Breakingviews) - Amazon.com’s (AMZN.O) cloud business is offering a small sliver of light. The performance matches last quarter’s growth and is in-line with what analysts were expecting, according to LSEG. Alphabet, in its earnings on Tuesday, said its similar unit’s growth rate slowed. Shares in the company led by Sundar Pichai declined by a tenth in two days. It’s not exactly a cloudless sky - AWS growth is slowing relative to last year, and its growth rate is still 10 percentage points below Alphabet’s.

Persons: Andy Jassy, Mike Blake, Sundar Pichai, It’s, Jennifer Saba, Lauren Silva Laughlin, Sharon Lam Organizations: Amazon Web Services, REUTERS, Reuters, North, X, Unilever, Thomson Locations: Laguna Beach , California, U.S, It’s

☆ EU’s best way to close its US growth gap: growth
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

BRUSSELS, Oct 26 (Reuters Breakingviews) - The European Union would have a better chance of catching the U.S. if it aimed for growth, instead of rearranging the regulatory deck chairs. Lowering political barriers in the 27-country single market could boost investment without breaking the bank on subsidies, Jean-François van Boxmeer told Breakingviews, citing a new European Round Table for Industry report. In the telecommunications sector, the European Commission has kept four providers in most of the EU’s markets, and screens out Chinese equipment-makers over security concerns. The European Commission reckons completing the single market by 2030 would hike EU GDP by 12%, or 713 billion euros. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: François van Boxmeer, Breakingviews, van Boxmeer, Jacob Wallenberg, Rebecca Christie, George Hay, Streisand Neto Organizations: Reuters, European, Vodafone, Reuters Graphics Business, EU, European Commission, Investor, X, News Corp, Thomson Locations: BRUSSELS

☆ This $5 Billion Biotech Home Run Took Less Than a Year
▼ + stars: | 2023-10-24 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Ownership of the drug went from Pfizer to Roivant and then to Roche with stunning speed. Photo: Stefan Wermuth/Bloomberg NewsYou can’t completely blame Pfizer ’s executives, yet Roche ’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look. In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer. Big pharma companies focused on the drug industry equivalent of free agent signings will often overlook one of their own hot prospects. In fact, Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharma’s trash can be another company’s treasure.

Persons: Roche, Stefan Wermuth, Pfizer ’, ” Roivant, Vivek Ramaswamy, Roivant Organizations: Pfizer, Roivant, Bloomberg, Street Journal, Big pharma, Republican

☆ A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
▼ + stars: | 2023-10-24 | by ( Filip De Mott | ) www.businessinsider.com time to read: +4 min

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.

Persons: Roche, Roivant, —, Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan

☆ Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
▼ + stars: | 2023-10-23 | by ( Adrià Calatayud | ) www.wsj.com time to read: 1 min

Roche’s deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs. Photo: Philipp Schmidli/Bloomberg NewsRoche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences , a company started by Republican presidential candidate Vivek Ramaswamy , and Pfizer in a deal worth more than $7 billion. The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.

Persons: Philipp Schmidli, Vivek Ramaswamy, Roche Organizations: pharma, Bloomberg, Roche Holding, Roivant Sciences, Republican, Pfizer, Telavant Holdings, Telavant’s Locations: Swiss, U.S, Japan

☆ Roche's $7 bln deal is pricey and partial cure
▼ + stars: | 2023-10-23 | by ( ) www.reuters.com time to read: +2 min

Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsNEW YORK, Oct 23 (Reuters Breakingviews) - Roche (ROG.S) has taken a small step towards curing its drug pipeline problem. JPMorgan analysts estimate that the drug’s U.S. sales could peak at 2.4 billion Swiss francs ($2.7 billion), but will take until 2037 to get there, assuming a 2028 launch. Analysts expect Roche’s pharmaceutical division to generate revenue of almost 45 billion Swiss francs this year, according to estimates compiled by LSEG. With expected free cash flow of around 16 billion Swiss francs this year and next, Roche can afford to buy a little more diversification.

Persons: Roche, Dado Ruvic, Thomas Schinecker, Peter Thal Larsen, Jean, Pierre Mustier, Atos, Jonathan Guilford, Aditya Sriwatsav Organizations: REUTERS, Reuters, Pfizer, U.S, New, JPMorgan, Merck, Prometheus Biosciences, Analysts, LSEG, X, News Corp, Thomson Locations: Swiss, U.S

New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage trial setbacks in the areas of Alzheimer's and cancer immunotherapy last year. The acquired drug, against inflammatory bowel disease such as ulcerative colitis and Crohn's disease, belongs to a class of new treatments known as anti-TL1A antibodies which has attracted major deal activity in the pharma industry. Merck & Co (MRK.N) in April agreed to buy anti-TL1A antibody developer Prometheus Biosciences for $10.8 billion. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission, Roche said. "We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," said Roche CEO Schinecker.

Persons: drugmaker Roche, Arnd, New Roche, Thomas Schinecker, Schinecker, Roche, John Revill, Ludwig Burger, Friederike Heine, Jason Neely Organizations: REUTERS, Roivant Holdings, Pfizer Inc, pharma, Sanofi, Merck & Co, Prometheus Biosciences, Thomson Locations: Basel, Switzerland, ZURICH, FRANKFURT, Swiss, U.S, Japan, Zurich, Frankfurt

☆ Stocks making the biggest moves premarket: Chevron, Apple, Walgreens Boots Alliance and more
▼ + stars: | 2023-10-23 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

Chevron , Hess — Chevron shares slumped more than 2% after the oil giant said its buying smaller rival Hess in an all-stock deal totaling $53 billion, or $171 a share. Hess shares moved slightly higher. Walgreens Boots Alliance — The pharmacy operator rose nearly 3% after JPMorgan upgraded Walgreens Boots Alliance shares to overweight from neutral. Salesforce — The software giant lost nearly 2% after Piper Sandler downgraded shares to neutral from overweight, citing heightened execution and M & A risks. Bank of America downgraded Alcoa to a neutral rating and slashed its price target, citing concerns of a near-term earnings decline.

Persons: Hess, Stonepeak, Piper Sandler, Roche, —, Jesse Pound Organizations: Hess, Chevron, Apple, Global Times, Walgreens, Alliance, JPMorgan, Roivant Sciences, Pfizer, Telavant Holdings, Citi, Evercore, Alcoa, Bank of America Locations: Chevron, China

☆ India is a ‘slow trundling elephant’ but a viable alternative to China, says veteran investor David Roche
▼ + stars: | 2023-10-23 | by ( Charmaine Jacob | ) www.cnbc.com time to read: +1 min

Veteran investor David Roche said India "is a slow trundling elephant" that still has many hurdles, but is now a viable alternative to China. "I think India stands to benefit from the decline in terms of the attractiveness of foreign direct investment and portfolio flows of China," Roche told CNBC's "Street Signs Asia" on Friday. After overtaking China to become the world's most populous nation, India could also leapfrog its neighbor to also become the world's second-largest economy by 2075. "So I think we're looking at a transfer of not only fixed investment by corporations, but portfolio investments out of China and into India," Roche said. "I think one has to look to sound the current levels and a note of caution about that," Roche warned.

Persons: David Roche, " Roche, CNBC's, Roche, Alicia Garcia, Herrero Organizations: China, Investors, Economic, CNBC Locations: India, China, Asia, Natixis

☆ Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings
▼ + stars: | 2023-10-23 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +1 min

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a "promising new therapy" for patients with Crohn's disease, Roche said in a press release. "We are eager to develop this antibody further and bring it to market and patients in the US and Japan as soon as possible." Telavant is currently owned by Pfizer and Roivant Sciences. In the Monday announcement, Roche also said it would obtain an option to collaborate with Pfizer on a new inflammatory bowel disease drug.

Persons: Roche, — Roche, Teresa Graham, Telavant Organizations: Monday, Telavant Holdings, Roche Pharmaceuticals, CNBC, Pfizer, Roivant Sciences Locations: Japan

Search resuls for: "Roche"

25 mentions found